CTKB Stock Price, Cytek Biosciences, Inc. Quote, Chart

Market Summary

USD5.76+0.13

Market Closed

2.31%

CTKB Alerts

1 major insider sales recently.

CTKB Stock Price

View Fullscreen

CTKB RSI Chart

CTKB Valuation

Market Cap

753.5M

Price/Earnings (Trailing)

-62.03

Price/Sales (Trailing)

3.9

EV/EBITDA

-77.24

Price/Free Cashflow

1.2K

CTKB Price/Sales (Trailing)

CTKB Profitability

EBT Margin

-8.14%

Return on Equity

-3.09%

Return on Assets

-2.46%

Free Cashflow Yield

0.08%

CTKB Fundamentals

CTKB Revenue

Revenue (TTM)

193.0M

Rev. Growth (Yr)

20.48%

Rev. Growth (Qtr)

21.32%

CTKB Earnings

Earnings (TTM)

-12.1M

Earnings Growth (Yr)

52.97%

Earnings Growth (Qtr)

185.24%

Breaking Down CTKB Revenue

Last 7 days

-2.7%

Last 30 days

-13.1%

Last 90 days

-32.1%

Trailing 12 Months

-47.3%

How does CTKB drawdown profile look like?

CTKB Financial Health

Current Ratio

6.97

CTKB Investor Care

Shares Dilution (1Y)

0.52%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	166.1M	175.6M	183.1M	193.0M
2022	138.7M	148.5M	154.6M	164.0M
2021	101.6M	110.4M	119.2M	128.0M
2020	0	0	0	92.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cytek Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	yan ming	sold	-117,400	5.87	-20,000	chief technology officer
Apr 09, 2024	yan ming	sold	-13,304	7.00211	-1,900	chief technology officer
Mar 20, 2024	busque philippe	acquired	-	-	5,464	svp, global sales and services
Mar 20, 2024	busque philippe	sold (taxes)	-14,264	6.7	-2,129	svp, global sales and services
Mar 19, 2024	yan ming	sold	-134,200	6.71	-20,000	chief technology officer
Mar 18, 2024	yan ming	sold	-135,400	6.77	-20,000	chief technology officer
Mar 11, 2024	poirson allen	sold (taxes)	-9,393	7.22	-1,301	svp bus. and corp. dev.
Mar 11, 2024	poirson allen	acquired	-	-	3,338	svp bus. and corp. dev.
Mar 11, 2024	barnett valerie	acquired	-	-	4,908	chief legal officer
Mar 11, 2024	jeanmonod patrik	sold (taxes)	-13,804	7.22	-1,912	chief financial officer

Which funds bought or sold CTKB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	-49,889	138,904	-%
Apr 25, 2024	NEW YORK STATE TEACHERS RETIREMENT SYSTEM	added	1.67	-125,000	372,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-5.33	-2,264,510	5,198,120	-%
Apr 25, 2024	Allworth Financial LP	sold off	-100	-374	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	1,163	-	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-1,822	5,073	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-24.48	-176,000	221,000	-%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-1.01	-122,650	328,790	0.01%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	226,735	574,396	-%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	-113,639	214,334	-%

Are Funds Buying or Selling CTKB?

Are funds buying CTKB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTKB

No. of Funds

CTKB Alerts

1 major insider sales recently.

Unveiling Cytek Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 22, 2024	ra capital management, l.p.	5.2%	6,809,404	SC 13G
Feb 14, 2024	brown capital management llc	8.86%	12,016,325	SC 13G
Feb 14, 2024	yan ming	4.7%	6,203,867	SC 13G/A
Feb 14, 2024	jiang wenbin	4.3%	5,702,130	SC 13G/A
Feb 14, 2024	hhlr advisors, ltd.	4.9%	6,657,030	SC 13G/A
Feb 13, 2024	vanguard group inc	8.77%	11,890,700	SC 13G/A
Jan 23, 2024	blackrock inc.	13.1%	17,779,753	SC 13G/A
Sep 19, 2023	ra capital management, l.p.	4.99%	6,809,404	SC 13D/A
May 05, 2023	blackrock inc.	10.9%	14,835,215	SC 13G/A
Feb 14, 2023	hhlr advisors, ltd.	6.4%	8,684,530	SC 13G/A

Recent SEC filings of Cytek Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 23, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	144	Notice of Insider Sale Intent
Mar 21, 2024	4	Insider Trading
Mar 20, 2024	3	Insider Trading
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Cytek Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

Cytek Biosciences, Inc. News

Latest updates

Cytek Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	21.3%	58,234	48,000	49,693	37,088	48,336	40,477	40,159	35,064	38,894	34,376	30,408	24,272	24,684	25,096	19,136
Gross Profit	21.6%	33,048	27,178	28,162	21,038	29,374	26,862	24,561	20,177	23,636	21,277	19,745	14,486	-	15,616	8,270
Operating Expenses	-1.2%	33,185	33,598	37,289	33,200	29,290	25,502	25,452	22,534	22,319	18,380	15,934	13,354	-	8,905	8,488
S&GA Expenses	-4.3%	11,561	12,076	14,367	11,145	9,029	8,810	8,431	6,960	8,304	6,553	5,576	4,277	-	3,838	3,059
R&D Expenses	-2.7%	10,870	11,171	12,136	9,974	9,747	8,650	8,436	8,025	7,076	6,078	6,194	5,094	-	3,376	2,916
EBITDA Margin	11.8%	-0.04*	-0.04*	-0.02*	0.01*	0.04*	0.02*	0.02*	0.05*	0.07*	0.13*	0.14*	0.15*	0.17*	-	-
Interest Expenses	-33.8%	394	595	409	673	687	649	647	590	492	441	433	375	-	2.00	1.00
Income Taxes	-161.3%	-1,392	2,271	-2,207	-2,233	396	224	-699	-1,145	1,609	655	597	50.00	-	357	-7,919
Earnings Before Taxes	198.2%	4,111	-4,185	-6,595	-9,040	4,114	1,850	-1,401	-3,303	444	2,075	3,267	152	-	6,897	192
EBT Margin	5.1%	-0.08*	-0.09*	-0.06*	-0.03*	0.01*	-0.02*	-0.01*	0.02*	0.05*	0.12*	0.13*	0.14*	0.16*	-	-
Net Income	185.2%	5,503	-6,456	-4,388	-6,807	3,598	1,626	-598	-2,021	-1,165	1,420	2,670	102	5,599	6,540	8,111
Net Income Margin	18.0%	-0.06*	-0.08*	-0.03*	-0.01*	0.02*	-0.01*	-0.02*	0.01*	0.02*	0.08*	0.14*	0.20*	0.21*	-	-
Free Cashflow	243.9%	8,012	-5,569	-4,163	2,353	-337	-8,614	-10,768	-2,260	4,152	-147	-5,165	1,426	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-4.8%	494	519	525	525	519	499	493	486	463	454	230	220
Current Assets	-7.2%	392	422	425	426	454	444	443	439	432	440	217	209
Cash Equivalents	2.2%	167	164	132	129	297	342	350	363	365	377	160	166
Inventory	-9.0%	61.00	67.00	66.00	70.00	48.00	49.00	45.00	38.00	32.00	28.00	27.00	23.00
Net PPE	5.7%	18.00	17.00	16.00	16.00	14.00	8.00	7.00	7.00	6.00	5.00	4.00	2.00
Goodwill	-1.7%	16.00	16.00	19.00	19.00	10.00	10.00	10.00	10.00	10.00	0.00	0.00	0.00
Liabilities	-2.4%	101	104	101	101	94.00	83.00	82.00	78.00	58.00	51.00	47.00	42.00
Current Liabilities	-4.2%	56.00	59.00	54.00	57.00	49.00	41.00	42.00	43.00	33.00	30.00	28.00	27.00
Shareholder's Equity	-5.4%	393	416	424	423	426	417	411	407	405	403	-	-16.03
Retained Earnings	15.9%	-29.18	-34.68	-28.22	-23.84	-17.03	-20.56	-22.22	-21.63	-19.61	-18.41	-19.83	-22.61
Additional Paid-In Capital	-6.3%	423	452	454	448	443	437	433	428	424	421	8.00	6.00
Shares Outstanding	-3.6%	131	136	136	136	135	135	134	134	77.00	58.00	32.00	29.00
Float	-	-	-	1,030	-	1,300	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	324.4%	9,512	-4,239	-2,850	2,858	6,193	-7,504	-9,440	-1,480	5,448	1,161	-3,914	1,935	-	-	-
Share Based Compensation	-1.5%	5,669	5,758	5,922	4,699	4,465	4,359	3,934	3,837	3,008	2,455	667	456	-	-	-
Cashflow From Investing	-32.6%	29,066	43,124	2,790	-168,874	-51,064	-1,150	-2,915	-780	-18,296	-1,308	-1,251	-138	-	-	-
Cashflow From Financing	-308.0%	-33,754	-8,274	216	-	3,850	155	1,144	364	17.00	217,078	-3,723	187	-	-	-
Buy Backs	310.5%	34,600	8,428	-	-	-	-	-	-	-	-	-	-	-	-	-

CTKB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive (loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue, net:
Total revenue, net	$ 193,015	$ 164,036	$ 127,950
Cost of sales:
Total cost of sales	83,589	63,062	48,806
Gross profit	109,426	100,974	79,144
Operating expenses:
Research and development	44,151	34,858	24,442
Sales and marketing	49,148	33,230	24,710
General and administrative	43,972	34,690	20,835
Total operating expenses	137,271	102,778	69,987
Income (loss) from operations	(27,845)	(1,804)	9,157
Other income (expense):
Interest expense	(2,071)	(2,573)	(1,741)
Interest income	6,413	4,619	49
Other income (expense), net	7,794	1,018	(1,527)
Total other income (expense), net	12,136	3,064	(3,219)
(Loss) income before income taxes	(15,709)	1,260	5,938
Provision for (benefit from) income taxes	(3,561)	(1,224)	2,911
Net (loss) income	(12,148)	2,484	3,027
Less: net loss (income) allocated to noncontrolling interests	0	92	(26)
Less: net income allocated to participating securities	0	0	(3,001)
Net income attributable to common stockholders, basic	(12,148)	2,576	0
Net income attributable to common stockholders, diluted	$ (12,148)	$ 2,576	$ 0
Net income attributable to common stockholders per share, basic (in dollars per share)	$ (0.09)	$ 0.02	$ 0
Net income attributable to common stockholders per share, diluted (in dollars per share)	$ (0.09)	$ 0.02	$ 0
Weighted-average shares used in calculating net income per share, basic (in shares)	135,283,044	134,510,831	76,741,858
Weighted-average shares used in calculating net income per share, diluted (in shares)	135,283,044	138,562,111	81,542,729
Comprehensive (loss) income:
Net (loss) income	$ (12,148)	$ 2,484	$ 3,027
Foreign currency translation adjustment, net of tax	(549)	(1,611)	832
Unrealized (loss) gain on marketable securities	(29)	17	0
Net comprehensive (loss) income	(12,726)	890	3,859
Product
Revenue, net:
Total revenue, net	156,717	148,600	119,519
Cost of sales:
Total cost of sales	65,327	49,955	37,377
Service
Revenue, net:
Total revenue, net	36,298	15,436	8,431
Cost of sales:
Total cost of sales	$ 18,262	$ 13,107	$ 11,429

CTKB Balance Sheet

2023-12-31

Consolidated Balance Sheets $ in Thousands	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Current assets:
Cash and cash equivalents	$ 167,299	$ 296,601
Restricted cash	331	2,899
Marketable securities	95,111	44,548
Trade accounts receivable, net	55,928	48,864
Inventories	60,877	48,154
Prepaid expenses and other current assets	12,514	12,954
Total current assets	392,060	454,020
Deferred income tax assets, noncurrent	30,487	20,459
Property and equipment, net	18,405	13,682
Operating lease right-of-use assets	10,853	13,883
Goodwill	16,183	10,144
Intangible assets, net	23,084	4,331
Other noncurrent assets	3,385	2,957
Total assets	494,457	519,476
Current liabilities:
Trade accounts payable	3,032	4,805
Legal settlement liability, current	2,561	2,163
Accrued expenses	20,035	21,126
Other current liabilities	7,903	7,960
Deferred revenue, current	22,695	12,986
Total current liabilities	56,226	49,040
Legal settlement liability, noncurrent	16,477	15,596
Deferred revenue, noncurrent	15,132	13,124
Operating lease liability, noncurrent	9,479	12,312
Long term debt	1,648	2,271
Other noncurrent liabilities	2,431	1,587
Total liabilities	101,393	93,930
Commitments and contingencies (Note 18)
Stockholders’ equity:
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of December 31, 2023 and December 31, 2022, respectively; 130,714,906 and 135,365,381 issued and outstanding shares as of December 31, 2023 and December 31, 2022, respectively.	131	135
Additional paid-in capital	423,386	442,887
Accumulated deficit	(29,178)	(17,030)
Accumulated other comprehensive loss	(1,275)	(697)
Noncontrolling interest in consolidated subsidiary	0	251
Total stockholders’ equity	393,064	425,546
Total liabilities and stockholders’ equity	$ 494,457	$ 519,476

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CEO	Dr. Wenbin Jiang Ph.D.
WEBSITE	https://cytekbio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	699

Cytek Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Cytek Biosciences, Inc.? What does CTKB stand for in stocks?

CTKB is the stock ticker symbol of Cytek Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytek Biosciences, Inc. (CTKB)?

As of Fri Apr 26 2024, market cap of Cytek Biosciences, Inc. is 753.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTKB stock?

You can check CTKB's fair value in chart for subscribers.

What is the fair value of CTKB stock?

You can check CTKB's fair value in chart for subscribers. The fair value of Cytek Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cytek Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTKB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cytek Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether CTKB is over valued or under valued. Whether Cytek Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Cytek Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTKB.

What is Cytek Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CTKB's PE ratio (Price to Earnings) is -62.03 and Price to Sales (PS) ratio is 3.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTKB PE ratio will change depending on the future growth rate expectations of investors.